C4 Therapeutics vs Kymera Therapeutics
CCCC and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CCCC and KYMR compare
Kymera Therapeutics is the larger company, worth 25 times as much as C4 Therapeutics ($10.5B against $415M).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus 2.3% for C4 Therapeutics).
C4 Therapeutics keeps more of each dollar of sales as profit, with a net margin of −289% compared with −342% at Kymera Therapeutics.
Kymera Therapeutics scores higher on the StockData Score (9 against 8 for C4 Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CCCC | KYMR |
|---|---|---|
| Size and price | ||
| Market cap | $415M | $10.5B |
| Share price | $3.37 | $126.63 |
| Change, 1 year | 34.3% | 111% |
| Change, 5 years | −92.5% | 95.0% |
| Beta (5Y) | 2.55 | 1.97 |
| Employees | 104 | 238 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 2 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.8× (better) | 103× |
| P/B | 1.7× (better) | 6.5× |
| FCF yield | −20.6% | −2.7% (better) |
| Fair value | $2.67 | $38.85 |
| Margin of safety | −26.1% (better) | −226% |
| Growth | ||
| Revenue growth (TTM) | 2.3% | 134% (better) |
| Revenue growth, 5Y average | – | 2.9% |
| Profitability | ||
| Gross margin | – | 0.00% |
| Operating margin | −319% (better) | −396% |
| Net margin | −289% (better) | −342% |
| FCF margin | −244% (better) | −283% |
| Return on equity | −48.1% | −27.3% (better) |
| Return on invested capital | – | −59.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.45 | 11.13 (better) |
| Altman Z-score | −1.06 | 40.23 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.06% | – |
| Shareholder yield | 0.06% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 95.6% | 117% |
| Held by insiders | 2.8% | 39.4% |
| Insider net buying, 12 months | −$22.2K (better) | −$297M |
| Short interest, % of float | 33.8% | 19.7% |
Go deeper
- CCCC stock overview
- CCCC income statement
- CCCC valuation and score
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.